Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis by Rebecca Anderson et al.
RESEARCH ARTICLE Open Access
Liposomal encapsulation enhances and prolongs
the anti-inflammatory effects of water-soluble
dexamethasone phosphate in experimental
adjuvant arthritis
Rebecca Anderson1,2, Angels Franch2, Margarida Castell2, Francisco J Perez-Cano2, Rolf Bräuer3, Dirk Pohlers1,
Mieczyslaw Gajda3, Alexandros P Siskos4, Theodora Katsila4, Constantin Tamvakopoulos4, Una Rauchhaus5,
Steffen Panzner5, Raimund W Kinne1*
Abstract
Introduction: The objective of this study was to evaluate the efficacy of intravenous (i.v.) injection of liposomally
encapsulated dexamethasone phosphate (DxM-P) in comparison to free DxM-P in rats with established adjuvant
arthritis (AA). This study focused on polyethylene glycol (PEG)-free liposomes, to minimize known allergic reactions
caused by neutral PEG-modified (PEG-ylated) liposomes.
Methods: Efficacy was assessed clinically and histologically using standard scores. Non-specific and specific
immune parameters were monitored. Activation of peritoneal macrophages was analyzed via cytokine profiling.
Pharmacokinetics/biodistribution of DxM in plasma, synovial membrane, spleen and liver were assessed via mass
spectrometry.
Results: Liposomal DxM-P (3 × 1 mg/kg body weight; administered intravenously (i.v.) on Days 14, 15 and 16 of
AA) suppressed established AA, including histological signs, erythrocyte sedimentation rate, white blood cell count,
circulating anti-mycobacterial IgG, and production of interleukin-1beta (IL-1b) and IL-6 by peritoneal macrophages.
The suppression was strong and long-lasting. The clinical effects of liposomal DxM-P were dose-dependent for
dosages between 0.01 and 1.0 mg/kg. Single administration of 1 mg/kg liposomal DxM-P and 3 × 1 mg/kg of free
DxM-P showed comparable effects consisting of a partial and transient suppression. Moreover, the effects of
medium-dose liposomal DxM-P (3 × 0.1 mg/kg) were equal (in the short term) or superior (in the long term) to
those of high-dose free DxM-P (3 × 1 mg/kg), suggesting a potential dose reduction by a factor between 3 and 10
by liposomal encapsulation. For at least 48 hours after the last injection, the liposomal drug achieved significantly
higher levels in plasma, synovial membrane, spleen and liver than the free drug.
Conclusions: This new PEG-free formulation of macrophage-targeting liposomal DxM-P considerably reduces the
dose and/or frequency required to treat AA, with a potential to enhance or prolong therapeutic efficacy and limit
side-effects also in the therapy of rheumatoid arthritis. Depot and/or recirculation effects in plasma, inflamed joint,
liver, and spleen may contribute to this superiority of liposomally encapsulated DxM-P.
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Introduction
Rheumatoid arthritis (RA) is a systemic disorder of
unknown etiology characterized by chronic inflamma-
tion and symmetric, progressive destruction of
arthritic joints. The abundance and activation of
macrophages (Mj) in the inflamed synovial membrane
significantly correlates with the severity of RA [1,2]. In
addition, activation of the monocytic lineage extends
to systemic parts of the mononuclear phagocyte sys-
tem [3-7]. Thus, selective counteraction of Mj activa-
tion is a promising approach to diminish local and
systemic inflammation or to prevent irreversible joint
damage.
In addition to disease-modifying anti-rheumatic drugs
(DMARDs) and to recently introduced biologicals (for
example, antibodies against tumor necrosis factor-
(TNF)-a or soluble TNF-a-receptors, [8-14]), anti-
inflammatory glucocorticoids are still frequently
employed to bridge the gap before the onset of action of
DMARDs [15-17] and to improve the therapeutic con-
trol of RA. Due to their unequalled efficacy, bridging
application and wide indication range (for example,
renal failure, pregnancy), glucocorticoids remain valu-
able therapeutic tools. However, concerns about long-
term side effects, such as Cushing syndrome or bone
demineralization, strongly emphasize the need for safer
treatment modalities. Specific targeting of glucocorti-
coids to phagocytic cells by liposomal encapsulation
potentially increases drug efficacy and longevity while
minimizing side-effects [18,19].
Previous studies have demonstrated good therapeutic
efficacy of water-soluble prednisolone in neutral poly-
ethylene glycol-modified (PEGylated) liposomes in ani-
mal models of arthritis and multiple sclerosis [20-23].
However, evidence has emerged that repeated injections
can result in the generation of anti-PEG antibodies,
emphasizing the need for a PEG-free liposomal formula-
tion [24-27].
In this study, water-soluble dexamethasone phosphate
(DxM-P) was encapsulated in a novel, non-PEGylated
liposome formulation (Micromethason). All lipids in this
formulation have market approval, thereby minimizing
the risk of lipid-associated toxicity. The efficacy of lipo-
somal DxM-P was evaluated in rat adjuvant arthritis
(AA), a severe animal model characterized by histo-
pathological similarities to RA, including both systemic
and local features of inflammation [28]. The effects of
treatment with free DxM-P or different doses of liposo-
mally-encapsulated DxM-P were also evaluated, in order
to assess the increase of therapeutic potency by encap-
sulation. In addition, a pharmacokinetics and biodistri-
bution study of DxM was carried out following
administration of liposomal DxM-P or free DxM-P.
Materials and methods
Micromethason preparation
Micromethason liposomes were prepared by Novosom
AG (Halle, Germany) from 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-
(phosphor-rac-(1-glycerol))(sodium salt) (DPPG) and
cholesterol (50:10:40 mol %; all lipids with market
approval) using the lipid film extrusion method [29].
The lipid film was hydrated with DxM-P (25 mg/ml in
phosphate-buffered saline (PBS), pH 7.5) and the result-
ing vesicles were extruded through 400 nm membranes.
Non-encapsulated DxM-P was removed by gel filtration.
Particle size (283 to 310 nm) and polydispersity (≤0.3)
were determined by dynamic light scattering. The drug/
lipid ratio was 40 μg/μmol (determined as in [30]) and
the concentration was adjusted to 500 μg DxM-P/ml.
The liposomes were selected for tolerability in vivo
and their ability to target cells of the macrophage-pha-
gocyte system while avoiding unwanted sites such as the
liver parenchyme. The latter was achieved by using
rather large particles, which cannot penetrate across the
150 nm fenestrations of liver endothelium [31]. The cel-
lular targeting to cells of the macrophage-phagocyte sys-




Female Lewis rats (seven to eight weeks of age) were
obtained from Harlan (Barcelona, Spain) and housed
three to four per cage under standard conditions, with
food and water ad libitum and a 12-hour-light/12-hour-
dark cycle. The animals were allowed two weeks to adjust
to the housing conditions prior to the initiation of stu-
dies. The experiments were performed in accordance
with the Institutional Guidelines for the Care and Use of
Laboratory Animals (Ethics Committee for Animal
Experimentation, Universities of Barcelona and Jena).
Experimental design
On Day 0, rats were injected intradermally (i.d.) into the
tail base with 0.5 mg of heat-killed Mycobacterium
butyricum (Mb) (Difco, Detroit, MI, USA) in 0.1 ml of
liquid vaseline as previously published [33]. Only ani-
mals developing clear signs of arthritis on Day 14
(arthritis score ≥2) were used for further studies (n = 6
for all groups). On Days 14, 15 and 16 of AA, anesthe-
tized rats were treated intravenously (i.v.; tail vein) with
1 mg/kg body weight liposomal DxM-P (AA/DxM-P-
liposomes; usually 250 μg/250 g body weight). Arthritic
controls were injected with either 3 × 1 mg/kg body
weight of free DxM-P (AA/DxM-P), an equal volume of
PBS (AA/PBS), or PBS-containing liposomes (AA/PBS-
liposomes). The healthy controls were not immunized
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and did not receive any treatment. For dose-response
studies, animals were treated with 3 × 0.01 mg/kg, 3 ×
0.1 mg/kg, or 3 × 1 mg/kg of liposomal or free DxM-P.
In addition, one group of rats received a single dose of
1 mg/kg of liposomal DxM-P on Day 14 of AA. In total,
three different arthritis studies were performed, that is,
Experiment 1 (treatment study; see Table 1 and Figure
1), Experiment 2/3 (two different animal subgroups of
the same treatment study containing both groups with
triple and single treatment with liposomal DxM; Table
1), and Experiment 4 (dose response; see Table 2 and
Figure 2).
Clinical parameters
Clinical signs of AA were assessed by measuring body
weight (precision scale), arthritis score (blinded grading
of each paw from 0 to 4 according to the extent of
edema and erythema of the periarticular tissue, as well
as the deformation of the joint; maximal score per ani-
mal: 16), and hind paw volume (water plethysmometer;
LI 7500 Letica, Spain). Except for the healthy controls,
all groups were normalized to the same mean value for
each parameter on Day 14; the volume of both hind
paws was averaged.
Histology
Animals were sacrificed on Day 21 of AA (that is,
shortly after the maximal efficacy of therapy) and the
hind paws were removed, skinned, fixed in 3% parafor-
maldehyde, decalcified, and embedded in paraffin.
Microtome sections (3 to 5 μm) of decalcified joints
were deparaffinized and stained with hematoxylin and
eosin (HE). Severity of arthritis was examined by blinded
grading of acute inflammation (graded from 0 (absent)
to 9 (very severe) according to the magnitude of granu-
locyte infiltration and exudates) and chronic inflamma-
tion (graded from 0 to 9 according to the magnitude of
synovial hyperplasia, mononuclear infiltration, and affec-
tion of periarticular structures), as well as joint and
bone destruction (each graded from 0 to 3). Parameters
were semi-quantitatively judged by an experienced
pathologist (MG).
Erythrocyte sedimentation rate (ESR), white blood cell count
(WBC), and differential leukocyte count
Blood samples were obtained by cardiac puncture of
anesthetized rats on Day 21 of AA. To determine the
ESR, 1 ml of tri-sodium citrate-treated blood was left to
sediment for one hour in capillaries (Tapval™ tubes,
Aquisel, Barcelona, Spain). The WBC was determined
automatically using a Coulter Counter JT hemocyt-
ometer (Hialeah, FL, USA) calibrated for rat blood, and
the differential white blood count was obtained by man-
ual enumeration of May-Grünwald-Giemsa-stained
blood cell smears.
Determination of serum anti-Mb antibodies
Anti-Mb immunoglobulin G (IgG) in rat sera (diluted
1:1.000 and 1:10.000 in BSA/PBS/0.05% Tween) was
measured by ELISA using Mb-coated microplates (3 μg/
ml of mycobacterial protein) as previously published
[33,34].
Delayed-type hypersensitivity
To assess the delayed-type hypersensitivity (DTH), 50 μl
Mb (1.5 mg/ml of PBS) and 50 μl PBS, respectively,
were injected intradermally into the left and right ear on
Table 1 Reduction of clinical parameters by liposomal dexamethasone phosphate on Days 19 and 28 of adjuvant
arthritis
Experiment 1 Arthritis score Paw volume
Treatment Day 19 Day 28 Day 19 Day 28
AA/PBS – – – –
AA/PBS-liposomes +23% ± 29.4% +36% ± 56.5% + 2% ± 38.8% +47% ± 62.3%
AA/DxM-P -51% ± 17.8% + 4% ± 41.7% -65% ± 14.0% -13% ± 26.4%
AA/liposomal DxM-P -95% ± 3.2%++ ## -54% ± 28.7% -92% ± 7.4%++ # -73% ± 17.3% +
Experiment 2/3 Arthritis score Paw volume
Treatment Day 19 Day 29* Day 19 Day 29*
AA/PBS – – – –
AA/PBS-liposomes +15% ± 19.8% +23% ± 20.3%
AA/DxM-P -67% ± 16.4% + # -52% ± 21.8% + #
AA/liposomal DxM-P -90% ± 5.0%++ ## -87% ± 6.6.%++ ##
AA/liposomal DxM-P 1× * -48% ± 23.9% -15% ± 29.6% -63% ± 24.6% -35% ± 22.6%
Reduction of arthritis score and paw volume on Day 19 (maximal efficacy of therapy) and Day 28 of AA after treatment with PBS-liposomes, free DxM-P (3 × 1
mg/kg; Days 14, 15 and 16), or liposomal DxM-P (3 × 1 mg/kg; Days 14, 15 and 16) compared to AA/PBS (Experiment 1 corresponds to the data in Figure 1). For
comparison, the effects of treatment with single-dose liposomal DxM-P (1 × 1 mg/kg; Day 14; Experiment 3) are shown. * results from a separate subgroup of
animals (named Experiment 3 for clarity) from the same arthritis study with similar disease severity on Days 19 and 20 as the other subgroup of animals (named
Experiment 2).
Data are expressed as means ± standard error of the mean.
+ P ≤ 0.05, ++ P ≤ 0.01 vs. AA/PBS; # P ≤ 0.05, ## P ≤ 0.01 vs. PBS-liposomes.
Anderson et al. Arthritis Research & Therapy 2010, 12:R147
http://arthritis-research.com/content/12/4/R147
Page 3 of 15
Day 19 (that is, 48 hours prior to sacrifice). The ears of
anesthetized rats were cut, weighed, and the DTH was
expressed as the x-fold enlargement in comparison to
the contra-lateral control ear.
Isolation of spleen and lymph node lymphocytes
Spleen and popliteal lymph nodes (the latter as draining
node of the arthritic hind paw; pop LN) were obtained
on Day 21. Spleen cell suspensions were prepared by
passing the samples through stainless steel sieves and
eliminating the erythrocytes by hypotonic lysis (consecu-
tive resuspension in 1 ml sterile PBS, 8 ml H2O, and 1
ml 10 × PBS). Pop LN were passed through stainless
steel sieves and sterile gauze to eliminate connective tis-
sue. After centrifugation (10 minutes; 600 × g), cell sus-
pensions were resuspended in RPMI 1640 plus 10%
FBS, and the lymphocytes counted using Fast Read®
chamber slides under fluorescence light after vital stain-
ing with acridine orange and ethidium bromide.
Isolation and stimulation of peritoneal Mj (PM)
PM were harvested on Day 21 by peritoneal lavage with
40 ml ice-cold PBS, centrifuged, washed, and resus-
pended in RPMI 1640 containing 10% FCS and 5% gen-
tamycine. Adherent Mj (1 × 106 cells per well of 12-
well plates after adherence for two hours at 37°C) were
stimulated for 24 hours with LPS (1 μg/ml; E coli; Sero-
type 0111:B4; Sigma-Aldrich, Munich, Germany). Cyto-
kines were analyzed in cell-free supernatants by ELISA
using rat TNF-a and rat IL-6 (BD Biosciences Pharmin-
gen, San Diego, CA, USA) or rat IL-1bkits (R&D Sys-
tems, Minneapolis, MN, USA).
Pharmacokinetics/biodistribution
The analysis of DxM concentrations in different body
compartments was performed as previously published
with slight modifications [35,36].
Materials
HPLC-grade acetonitrile (AcCN) was purchased from
Fisher Scientific (Loughborough, UK). HPLC-grade
ammonium acetate (NH4Ac) and HPLC-grade formic
acid (FA) were purchased from Sigma-Aldrich (Athens,
Greece). Purified water was produced using a Barnstead
NANOpure Diamond water system from Barnstead
International (Dubuque, IA, USA). DxM and predniso-
lone were purchased from Riedel-de Haen (ChemiLab,
Athens, Greece).
Preparation of standards and calibration curve for method
validation
Prednisolone was used as an internal standard (IS) for the
quantitative analysis of DxM. Stock solutions of both
DxM (5 to 10,000 ng/ml) and prednisolone (1 μg/ml) were
prepared in methanol. Calibration curves (2 to 4,000 ng/
ml; limit of quantification 2 ng/ml) and quality control
samples (800 ng/ml) in plasma were prepared daily by
adding 20 μl of DxM and 20 μl of IS solutions into 50 μl
of plasma. For tissue analysis, calibration curves were con-
structed daily in a similar manner by adding standards of
DxM and IS into 100 μl of tissue homogenate (liver, spleen
or synovial membranes) at concentrations of 2.5 to 2,000
ng/g (limit of quantification 2.5 ng/g). Calibration curves
were constructed using a linear fit (1/x2 weighing) in the
concentration range of 2 to 4,000 ng/ml for plasma and
2.5 to 2,000 ng/g for the tissues. The accuracy in the
Figure 1 Clinical effects of free or liposomal DxM-P in adjuvant
arthritis (Experiment 1). Effect of treatment with PBS-liposomes,
free DxM-P (3 × 1 mg/kg; Days 14, 15 and 16), or liposomal DxM-P
(3 × 1 mg/kg; Days 14, 15 and 16) on arthritis score (a), paw
volume (b), and body weight (c); all arthritic groups were
normalized to the same mean value for each parameter on Day 14
(n = 6 each). The inserts show the area under the curve (AUC) from
Day 0 to Day 30 for the arthritis score (a) and the paw volume (b);
dashed line: healthy control levels. For all treatment groups: + P ≤
0.05, ++ P ≤ 0.01 vs. AA/PBS; # P ≤ 0.05, ## P ≤ 0.01 vs. AA/PBS-
liposomes; * P ≤ 0.05 vs. AA/DxM-P; For AA/liposomal DxM-P: o P ≤
0.05, oo P ≤ 0.01 vs. healthy controls; all Mann Whitney U-test; ↑ I. v.
administration of PBS, PBS-liposomes, free DxM-P, or liposomal DxM-
P.
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concentration range was ±20% (that is, target concentra-
tions were within 20% of nominal values). The recovery of
DxM was evaluated in rat plasma (96% at a concentration
of 200 ng/ml) and in rat liver (91% at a concentration of
1,000 ng/g).
Tissue/organ sampling
Heparinized plasma samples were obtained by retro-
orbital puncture and subsequent centrifugation 30 min-
utes, 2 hours, 8 hours, and 24 hours after the first
administration of free or liposomal DxM-P (1 mg/kg
each; 1st administration = time point 0 for pharmaco-
kinetic results; Day 14 of AA), as well as 72 hours,
96 hours, and 9 days after the first dose (these animals
received a total of three drug administrations). Synovial
membrane, spleen, and liver where also obtained
72 hours, 96 hours, and 9 days after the first injection
(total of three doses); all samples were immediately
shock frozen in liquid nitrogen.
Sample preparation
Plasma Prior to the extraction procedure, 20 μl of the
IS solution was added to 50 μl of mouse plasma. Sam-
ples were prepared for LC/ESI-MS/MS analysis by pro-
tein precipitation by addition of 100 μl acetonitrile:water
(50:50), followed by stepwise addition of (2 × 150 μl) of
ice-cold acetonitrile and brief vortexing and sonication.
The samples were subsequently centrifuged (12,000 × g)
for 15 minutes, and the supernatant was transferred into
glass tubes and evaporated in a SpeedVac SPD1010
(Thermo Fisher Scientific Inc., Waltham, MA, USA) for
70 minutes at 50°C. Until analyzed, samples were stored
at -20°C. An aliquot of 200 μl of mobile phase of the
initial chromatographic conditions A/B 95/5 was added
to each sample, vortexed, and transferred onto a 96-well
plate for analysis by LC/ESI-MS/MS.
Tissues/organs Synovial membrane, spleen, or liver
homogenates were prepared as follows: tissues were
washed once with 5 ml of water. Water was decanted
after washing and 4 ml of 0.1% formic acid in water per
g of tissue were added to the respective tissues. The
mixture was homogenized in an Ultra-Turrax T8 homo-
genizer (IKA®-Werke, Germany) and subsequent analysis
was carried out immediately after homogenization. Prior
to the extraction of DxM from tissue homogenates, 20
μl of the IS solution was added to 100 μl of tissue
homogenate. Samples were prepared for LC/ESI-MS/MS
analysis by protein precipitation via addition of 200 μl
acetonitrile:water (50:50), followed by stepwise addition
of (2 × 300 μl) of ice-cold acetonitrile and brief vortex-
ing/sonication. The samples were subsequently centri-
fuged for 15 minutes, and the supernatant was
transferred into glass tubes and evaporated in a Speed-
Vac SPD1010 for 70 minutes at 50°C. Samples were
stored at -20°C. An aliquot of 100 μl of mobile phase of
the initial chromatographic conditions A/B 95/5 was
added to each sample, vortexed, and transferred onto a
96-well plate for analysis by LC/ESI-MS/MS.
LC-MS/MS analysis
HPLC was performed with an Agilent 1100 Series sys-
tem (Agilent Technologies, Waldbrown, Germany)
equipped with a binary pump, autosampler, vacuum
degasser, and temperature-controlled column compart-
ment. The mobile phase consisted of solvents A: 10%
acetonitrile, 90% water, 2 mM ammonium acetate, 0.1%
formic acid and B: 90% acetonitrile, 10% water, 2 mM
ammonium acetate, 0.1% formic acid. A Waters Symme-
try C8 3.5 μm, 2.1 × 50 mm column (Waters Corpora-
tion, Milford, MA, USA) was used at a flow rate of 0.3
ml/minute. The analytical gradient profile was as follows
(minute/% of B): 0/5, 1/5, 6/50, 9/50, 11/5, 14/5, total
run time 14 minutes. The typical injection volume was
10 μl. Mass spectrometry was performed on an API
4000 QTRAP™ LC-MS/MS system fitted with a
Table 2 Dose-dependent reduction of clinical parameters by liposomal dexamethasone phosphate on Days 19 and 28
in adjuvant arthritis
Experiment 4 Arthritis score Paw volume
Treatment Day 19 Day 28 Day 19 Day 28
AA/PBS – – – –
AA/DxM-P 0.01 mg/kg -10% ± 9.3% + 6% ± 11.9% -18% ± 12.9% -12% ± 8.4%
AA/DxM-P 0.1 mg/kg -25% ± 6.9% -4% ± 10.3% -34% ± 10.1% + 9% ± 27.0%
AA/DxM-P 1.0 mg/kg -69% ± 12.5% + -27% ± 16.4% -71% ± 10.4% + -23% ± 16.0%
AA/liposomal DxM-P 0.01 mg/kg -20% ± 14.0% -13% ± 18.5% -21% ± 21.1% -5% ± 26.7%
AA/liposomal DxM-P 0.1 mg/kg -38% ± 23.7% -28% ± 16.9% -44% ± 15.4% -36% ± 12.2%
AA/liposomal DxM-P 1.0 mg/kg -96% ± 2.0% ++ $$ § * -59% ± 20.0% -86% ± 5.1% ++ $$ §§ -58% ± 18.0%
Reduction of arthritis score and paw volume on Day 19 (maximal efficacy of therapy) and Day 28 of AA after treatment with free DxM-P (3 × 1 mg/kg, 3 × 0.1
mg/kg, or 3 × 0.01 mg/kg) or liposomal DxM-P (3 × 1 mg/kg, 3 × 0.1 mg/kg, or 3 × 0.01 mg/kg) compared to AA/PBS (Experiment 4 corresponds to the data in
Figure 2).
Data are expressed as means ± standard error of the mean.
+ P ≤ 0.05, ++ P ≤ 0.01 vs. AA/PBS; $$ P ≤ 0.01 vs. AA/liposomal DxM-P 0.01 mg/kg; § P ≤ 0.05, §§ P ≤ 0.01 vs. AA/liposomal DxM-P 0.1 mg/kg; * P ≤ 0.05 vs. AA/
DxM-P 1 mg/kg.
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TurboIonSpray source and a hybrid triple quadrupole/
linear ion trap mass spectrometer (Applied Biosystems,
Concord, ON, Canada). The instrument was operated in
positive ion mode with an IonSpray voltage of 5500 V, a
source temperature of 550°C, curtain gas (nitrogen) at
20, collision gas (nitrogen) at 5, ION source gas 1 (air)
at 40 and Ion source gas 2 (air) at 45 (all arbitrary
units). Quantification was performed in the MRM posi-
tive mode. For the detection of DxM (MW: 392.5), the
transitions of m/z 393.6 ® 373.4, m/z 393.6 ® 355.5
and 393.6 ® 337.4 were optimized by adjustments of
collision energy, declustering potential and dwell time.
IS (prednisolone MW: 360.4) was monitored using the
MRM transition of m/z 361.6 ® 343.3. The lower limit
of quantification was 2.0 ng/ml in plasma and 2.5 ng/g
in tissue.
The analytical procedure focussed on rigorous and
validated quantification of DxM as the pharmacologi-
cally relevant analyte. In selected spleen samples, DxM-
P detection was also accomplished in the negative ioni-
zation mode following assessment of: i) selectivity of the
analysis for DxM and DxM-P; and ii) autosampler
stability.
Statistics
Differences among groups were analyzed using the
Mann Whitney U-Test (P ≤ 0.05), correlations among
variables using the Spearman rank correlation (both
SPSS 13.0™; SPSS Inc.; Chicago, IL, USA).
Results
Clinical effects of Micromethason therapy in AA
Short term i.v. treatment of established AA with liposo-
mal DxM-P on Days 14, 15 and 16 (3 × 1 mg/kg body
weight) resulted in a strong, significant, and long-lasting
suppression of arthritis score and paw volume to almost
normal levels (Figure 1a, b; Table 1). On Day 28, that is,
two weeks after the initiation of treatment, liposomal
DxM-P still reduced the arthritis score by 54% and the
paw volume by 73% (Table 1). Despite a significant, but
transient drop of the body weight after therapy with
liposomal DxM-P (Figure 1c), the treatment was well
tolerated by the rats, which showed an active and
mobile behavior from Day 15 onwards. In contrast, the
same dosage of free DxM-P (3 × 1 mg/kg) only transi-
ently reduced the arthritis score by 51% and the paw
volume by 65%, with a strong rebound starting two days
after the end of therapy (Figure 1a, b; Table 1). PBS-
liposomes were ineffective or even induced a transient,
numerical increase of the clinical signs (Figure 1a, b;
Table 1).
Similar results were obtained in two independent
repeats (Table 1; Experiments 2/3 and Table 2; Experi-
ment 4), confirming the validity of the data.
Interestingly, reduction of the area under the curve
(AUC from Day 0 to Day 30) by liposomal DxM-P
reached almost 54% for the arthritis score (P ≤ 0.05;
19% with free DxM-P) and 74% for the paw swelling
(P ≤ 0.05; 36% with free DxM-P; see inserts in
Figure 1a, b).
Dose-response experiments
The effects of liposomal DxM-P were dose-dependent
(Figure 2a-c; Table 2), that is, inhibition of arthritis
Figure 2 Dose-dependence of liposomal DxM-P in adjuvant
arthritis (Experiment 4). (a-c): Dose-response of treatment with
liposomal DxM-P (3 × 1 mg/kg, 3 × 0.1 mg/kg, or 3 × 0.01 mg/kg);
all groups were normalized to the same mean value for each
parameter on Day 14 (n = 6 each). + P ≤ 0.05, ++ P ≤ 0.01 vs. AA/
PBS; $ P ≤ 0.05, $$ P ≤ 0.01 vs. AA/DxM-P-liposomes 0.01 mg/kg; §
P ≤ 0.05, §§ P ≤ 0.01 vs. AA/DxM-P-liposomes 0.1 mg/kg, * P ≤ 0.05
vs. AA/DxM-P 1 mg/kg; all Mann Whitney U-test. ↑ administration of
PBS or liposomal DxM-P.
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score and paw swelling was significantly stronger after
administration of high-dose liposomal DxM-P than after
low-dose and medium-dose liposomal DxM-P (Figure
2a, b; Table 2).
Efficacy differences between liposomal and free DxM-
P were dose-dependently potentiated. Compared to free
DxM-P, the reduction of the arthritis score on Day 19
was 10% higher with low-dose liposomal DxM-P, 13%
higher with medium-dose DxM-P, and 27% higher with
high-dose DxM-P (Table 2). The differences between
high-dose liposomal DxM-P and high-dose free DxM-P
were significant for the reduction of arthritis score (P ≤
0.05, Days 16 to 19), paw volume (P ≤ 0.05, Day 18),
but also the reduction of body weight (P ≤ 0.05, Days 17
and 18; data not shown).
Single-dose liposomal DxM-P
Single-dose therapy with liposomal DxM-P (1 mg/kg) on
Day 14 caused a significant, but short-lasting reduction
of arthritis score (P ≤ 0.05 vs. AA/PBS on Day 15; P ≤
0.08 on Days 16 and 17) and paw volume (P ≤ 0.05 vs.
AA/PBS on Day 15; P ≤ 0.06 on Days 16, 17 and 19;
data not shown). The magnitude of the effects on Days
19 and 29 were similar or even superior to those after
therapy with three × free DxM-P in the same experi-
mental group of animals (1 mg/kg; Table 1; experimen-
tal subgroups named Experiment 2 and 3).
In all groups, the paw volume on Day 19 showed a
significant, positive correlation with the volume before
treatment (Day 14; P ≤ 0.005, rs ≥ 0.87; n = 30; Figure
3). The regression line gradient for rats treated three ×
with high-dose liposomal DxM-P was k = 0.33, whereas
that for PBS-treated rats was 1.26. These results show
that three × administration of liposomal DxM-P strongly
controlled the swelling even in the case of established,
severe AA. The regression line gradient of three × treat-
ment with liposomal DxM-P was smaller than that of
one × treatment with liposomal DxM-P, indicating the
dose-dependent effect on arthritis. Rats treated one ×
with liposomal DxM-P or three × with free DxM-P
showed similar gradients (k = 0.9 and 0.86, respectively)
and thus comparable therapeutic efficacy (Figure 3).
Histological results
On Day 21, untreated arthritic animals showed massive
infiltration with acute/chronic inflammatory cells and
synovial hyperplasia, as well as marked loss of bone and
cartilage (Figure 4c). Both free DxM-P and liposomal
DxM-P significantly inhibited acute granulocytic inflam-
mation and joint destruction, although some chronic
infiltration of mononuclear cells, synovial hyperplasia,
and deformation persisted (Figure 4a, e-f). Signs of
chronic and especially acute inflammation were reduced
to a somewhat greater extent by liposomal than by free
DxM (data not shown).
Hematological results
ESR
Only liposomal DxM-P treatment (3 × 1 mg/kg) signifi-
cantly reduced the ESR (60% and 65% reduction, respec-
tively, vs. AA/PBS or AA/PBS-liposomes; Figure 5a).
Total and differential WBC
AA rats treated with free DxM-P showed only a partially
decreased (20 to 30%) leukocytosis compared to AA/
PBS (Figure 5b). In contrast, liposomal DxM-P comple-
tely reversed the leukocytosis observed in untreated AA,
showing a WBC count similar to that of healthy con-
trols (P ≤ 0.01; significantly stronger inhibition than that
achieved by PBS-liposomes, P ≤ 0.05).
Untreated AA was characterized by a significant, rela-
tive neutrophilia (increase of polymorphonuclear neutro-
philic leukocytes (PMN) from 19 to 48%) and a relative
lymphopenia (decrease of lymphocytes from 77 to 48%;
Figure 5c). PBS-liposomes had no effect on PMN or
Figure 3 Correlation between the paw volume on Days 14 and
19 during the time course of adjuvant arthritis. Correlation
(Spearman rank test, rs) between the paw volume on Day 19
(maximal efficacy of treatment) and Day 14 (prior to treatment) of
individual rats treated with PBS (3 ×; Days 14, 15 and 16; n = 8), free
DxM-P (3 × 1 mg/kg; Days 14, 15 and 16; n = 8), or liposomal DxM-
P (3 × 1 mg/kg; Days 14, 15 and 16; n = 8; or 1 × 1 mg/kg; Day 14;
n = 6). The solid, dashed, and dotted lines are the regression lines, k
represents the regression gradient.
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lymphocyte count. The absolute number of PMN was
significantly decreased by liposomal DxM-P (P ≤ 0.05
vs. AA/PBS; Figure 5d), but not by free DxM-P. Despite
their clear therapeutic efficacy, however, both free DxM-
P and liposomal DxM-P led to a further, significant
decrease of absolute and relative lymphocyte counts
(decrease to 33% and 29%, respectively; Figure 5c, d)
and to an increase of the percentages of PMN (increase
to 57% and 64%, respectively).
The relative reduction of lymphocytes and the relative
increase of PMN were more prominent with liposomal
DxM-P than with free DxM-P. The lymphocyte percen-
tage was significantly lower (the PMN percentage
higher) after free DxM-P or liposomal DxM-P than in
PBS-treated AA rats (Figure 5c).
Immune status
Delayed-type hypersensitivity
Little reaction was observed after i.d. injection of Mb
solution in the ear. Only AA rats treated with liposomal
DxM-P showed a significantly higher DTH than healthy
or arthritic controls (P ≤ 0.05; Figure 5e).
Figure 4 Histological effects of liposomal DxM-P in adjuvant arthritis (Day 21; Experiment 2/3). Inflammation and destruction score (a)
and images of HE-stained joints sections from healthy controls (b) or arthritic rats after treatment with PBS (c), PBS-liposomes (d), free DxM-P
(e), or liposomal DxM-P (f) (for details see Figure 1). + P ≤ 0.05, ++ P ≤ 0.01 vs. AA/PBS; # P ≤ 0.05, ## P ≤ 0.01 vs. AA/PBS-liposomes; all Mann
Whitney U-test.
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Anti-Mb IgG in serum
The levels of anti-Mb IgG were significantly reduced by
liposomal DxM-P from Day 26 onwards, reaching
healthy control levels on Day 36 (Figure 5f). No signifi-
cant differences were observed between liposomal DxM-
P and free DxM-P, although the decrease of serum anti-
Mb IgG was somewhat more rapid after liposomal
DxM-P therapy (Figure 5f).
Blood lymphocytes
Free and liposomal DxM-P significantly reduced the
number of circulating lymphocytes, in the case of lipo-
somal DxM-P down to 0.49 × 109 cells/L (Figure 6a).
Spleen lymphocytes
In AA rats, liposomal DxM-P significantly reduced the
lymphocyte numbers in the spleen to healthy control
values (44 × 106 cells), whereas free DxM-P and PBS-
liposomes had no significant effect on the lymphocyte
infiltration (Figure 6b).
Pop LN lymphocytes
Only liposomal DxM-P counteracted the lymphocyte
infiltration in the pop LN, leading to numbers below
those of healthy controls (0.25 × 106 cells; Figure 6c).
Free DxM-P had no effect.
Cytokine production by peritoneal Mj (PM)
In non-stimulated PM (Figure 7a) or stimulated PM
(Figure 7b-d), the cytokine production did not signifi-
cantly differ between healthy and PBS-treated AA rats
(data only shown for IL-6).
IL-6
In non-stimulated PM, previous in vivo treatment with
PBS-liposomes or liposomal DxM-P significantly reduced
the IL-6 production (Figure 7a). In contrast, in LPS-stimu-
lated PM, only liposomal DxM-P significantly reduced the
IL-6 production. These effects were significantly stronger
than those observed with free DxM-P (Figure 7b).
Figure 5 Hematological parameters (Day 21) and anti-Mb IgG response (Days 17 to 36) in adjuvant arthritis (Experiment 2/3).
Erythrocyte sedimentation rate (ESR) (a), white blood cell count (WBC) (b), differential WBC in relative percentages (c) and absolute numbers of
leukocytes (d), delayed type hypersensitivity (DTH) (e), and time course of serum anti-Mb IgG (f) after treatment as in Figure 1; n = 8 for all
groups. + P ≤ 0.05, ++ P ≤ 0.01 vs. AA/PBS; # P ≤ 0.05, ## P ≤ 0.01 vs. AA/PBS-liposomes; (*) P ≤ 0.085 vs. AA/DxM-P; all Mann Whitney U-test.
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TNF-a
No effects of any in vivo therapy on TNF-a secretion
were observed in non-stimulated PM (data not shown)
or LPS-stimulated PM (Figure 7c).
IL-1b
No significant effects were observed in non-stimulated
PM (data not shown). IL-1b secretion in LPS-stimulated
PM was significantly reduced by in vivo treatment with
PBS-liposomes or liposomal DxM-P (Figure 7d; free
DxM-P failed to reach statistical significance).
Pharmacokinetics/biodistribution of DxM
DxM was measured as the pharmacologically relevant
species in plasma and tissues, since the pro-drug DxM-
P is rapidly converted in body fluids.
Plasma
DxM concentrations in the circulating blood rapidly
decreased within the first 24 hours after injection of
either liposomal or free DxM-P. However, plasma con-
centrations following the injection of liposomal DxM-P
remained above 20 ng/mL (50 nM) throughout the 96
hours time point, significantly higher than those after
injection of free DxM-P (approximately 2.8-fold at 0.5
hours; 17.7-fold at 24 hours; 14-fold at 72 hours, and
≥10-fold at 96 hours; all P < 0.01; Figure 8a).
Synovial membrane, spleen, and liver
No DxM was detectable in the synovial membrane of
AA rats treated with free DxM-P at any time point
investigated, while use of liposomal drug resulted in
deposition of DxM at 72 hours and 96 hours (Figure
8b). Also, DxM concentrations in both spleen and liver
were significantly higher 72 hours and 96 hours after
treatment with liposomal DxM-P (P < 0.05, Figure 8c,
d).
After 288 hours (nine days), the levels of DxM in
almost all of the samples were below the quantification
limit (2.0 ng/ml in plasma or 2.5 ng/g in tissues).
The present pharmacokinetic analysis focused on
absolute concentrations of DxM as the pharmacologi-
cally relevant analyte. However, in selected spleen sam-
ples, DxM-P was also detected using a modification of
the analytical procedure (LC followed by detection in
the negative ionization mode). DxM-P in the spleen
showed average levels of approximately 100 ng/g and 10
ng/g tissue at 72 hours and 96 hours, respectively, fol-
lowing injection of liposomal DxM-P, that is, similar to
those of the corresponding DxM.
Discussion
Intravenous therapy with liposomal DxM-P in estab-
lished AA (analogous to the clinical situation in RA)
suppressed joint swelling and inflammation in a signifi-
cant, dose-dependent, and long-lasting manner. Notably,
liposomal DxM-P showed superior therapeutic efficacy
in both early and advanced disease compared to
matched doses of free DxM-P. Liposomal encapsulation,
therefore, clearly potentiates the clinical efficacy of the
well-established anti-rheumatic glucocorticoid (GC)
DxM-P.
This superior efficacy is already achieved upon short-
term treatment for three days, similar to successful,
long-term suppression of human RA [37] and rat anti-
gen-induced arthritis (including an approximately 80%
reduction of a flare-up induced seven days after the end
of treatment) [19]. The prolonged efficacy may represent
Figure 6 Effects of liposomal DxM-P on lymphocytes in
adjuvant arthritis (Day 21; Experiment 2/3). Assessment of
lymphocytes in blood (a) (n = 8), spleen (b) (n = 4) and pop LN (c)
(n = 4) after treatment with PBS, PBS-liposomes, free DxM-P, or
liposomal DxM-P (for details see Figure 1). + P ≤ 0.05, ++ P ≤ 0.01
vs. AA/PBS; # P ≤ 0.05, ## P ≤ 0.01 vs. PBS-liposomes; * P ≤ 0.05 vs.
AA/DxM-P; all Mann Whitney U-test.
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a substantial advantage in the treatment of RA, with the
potential to obtain therapeutic effects with lower and/or
less frequent doses. Of interest, the AUC for arthritis
score/paw volume was more markedly reduced by lipo-
somal than by free DxM-P, suggesting a decrease of the
cumulative disease activity altogether.
Pharmacokinetic/biodistribution results showed a
slower elimination of the liposomal drug from the circu-
lation, confirming previous results [38], and substantially
higher levels and longer persistence of the liposomal
form of the drug in synovial membrane, spleen and liver
until at least 48 hours after the last injection. These
depot effects likely contribute to the superior and pro-
longed clinical efficacy of the encapsulated formulation.
Enhanced therapeutic efficacy extended until Day 9 post
injection of the first dose (corresponding to Day 23 of
AA; Figure 1), although no DxM was detectable in
blood or synovial tissue at this time point. Typical GC-
receptor mediated drug actions require 1 nM concentra-
tions or less of DxM, a level that is below the quantifi-
cation limit of 5 nM (2 ng/ml) of the LC-MS method
employed. Residual liposomal drugs in circulation and/
or tissues may thus contribute to the persistence of clin-
ical effects [19].
In an independent arthritis study, administration of
one dose of liposomal DxM-P (1 mg/kg) and three
doses of free DxM-P (3 × 1 mg/kg) showed comparable
therapeutic efficacy. In addition, long-term suppression
of AA by three medium doses of liposomal DxM-P (3 ×
0.1 mg/kg) was basically equivalent to that of three high
doses of free DxM-P (3 × 1 mg/kg). Furthermore, blood
DxM concentrations 24 hours after a single dose of lipo-
somal administration (1 mg/kg) were 17-fold and 5-fold
higher, respectively, than 24 hours after a single or triple
administration of free drug (one or three doses of 1 mg/
kg). Thus, the present results indicate that liposomal
encapsulation allows a dose reduction by a factor of at
least 3, if not 10. Also, the difference between the clini-
cal efficacy of matched doses of liposomal and free
DxM-P was augmented with rising DxM-P concentra-
tions, suggesting that potentiation by liposomal encapsu-
lation may be enhanced by a higher dose of DxM-P.
Dose reductions via encapsulation have been recently
described in AA with prednisolone-containing PEGylated-
liposomes [22,23]. Avnir et al. [23] achieved an effective
suppression of arthritis by administering two or three
doses of 10 mg/kg methylpredisolone either in early AA
(Days 10 and 14, or Days 10, 14 and 18) or in established
AA (Days 19 and 23) using PEGylated, remote-loaded
liposomes. The latter results are very similar to those of
the present study, in particular when considering the dif-
ferences between methylprednisolone and DxM in terms
of glucocorticoid equivalent. To our knowledge, however,
this study provides the first evidence of a prolonged and
Figure 7 Cytokine production by peritoneal Mj in adjuvant arthritis (Day 21; Experiment 2/3). IL-6 (a-b), TNF-a (c), and IL-1b (d)
production by non-stimulated and LPS-stimulated peritoneal Mj after treatment as in Figure 1; n = 4 for all groups. + P ≤ 0.05, ++ P ≤ 0.01 vs.
AA/PBS; # P ≤ 0.05 vs. AA/PBS-liposomes; * P ≤ 0.05 vs. AA/DxM-P; all Mann Whitney U-test.
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nearly 100% remission in severe established AA with
DxM-P in non-PEGylated liposomes.
The long-term benefit of short-term therapy with lipo-
somal DxM-P was histologically confirmed by significant
reduction of inflammation, as well as bone and cartilage
destruction. At this relatively early stage of disease (Day
21), the histological effects of free DxM-P were similar
to those of liposomal DxM-P, and did not yet reflect the
clinical rebound observed with free DxM-P after Day
19. Interestingly, only liposomal DxM-P accumulated in
the inflamed synovial membrane, matching the targeting
of the inflamed joint achieved by other novel liposome
formulations [23]. Based on the known direct and indir-
ect contribution of synovial Mj to cartilage and bone
destruction via TNF-a, IL-1b, or IL-6 [2,3,7,39], the pre-
sent histological findings suggest that both Mj activa-
tion and secretion of pro-inflammatory mediators are
inhibited by effectively targeting these cells with liposo-
mal DxM-P. Local efficacy of liposomal DxM-P
extended to periarticular tissue (data not shown) and
pop LN, in which liposomal (but not free) DxM-P
reduced the number of lymphocytes presumably
involved in regional perpetuation of inflammation [40].
The present study demonstrates for the first time that,
in contrast to free DxM-P, i.v.-injected liposomal DxM-
P showed systemic anti-inflammatory effects by pro-
foundly decreasing ESR and total WBC during acute
and chronic AA. Although leukocytosis in PBS-treated
AA was already paralleled by an increase of the relative
percentage of PMN and a reduction of the lymphocyte
percentage, both free DxM-P and liposomal DxM-P
caused a further significant decrease of circulating lym-
phocytes. Lymphocytes were reduced to levels below
50% and 75% of those in healthy controls by both free
and liposomal DxM-P, respectively, suggesting that lym-
phopenia may be the result of direct DxM effects in
addition to indirect effects via Mj inactivation.
Free GCs, in particular DxM-P, are known to diminish
the number of circulating lymphocytes via two mechan-
isms [41]: 1) redistribution to spleen, lymph nodes, bone
marrow, and perivascular compartments; 2) induction of
cell apoptosis. In the present study, however, signifi-
cantly lower numbers of lymphocytes in lymphoid
organs were observed after therapy with liposomal
DxM-P, suggesting that redistribution to spleen and LN
either did not occur or was balanced by increased local
Figure 8 Biodistribution of free or liposomal DxM-P in adjuvant arthritis. Concentration of DxM in blood (a) (n = 6), synovial membrane
(b) (n = 3), spleen (c) (n = 3), and liver (d) (n = 3) at 0.5, 2, 8, 24, and/or 72, 96, and 288 hours after the initial i. v. treatment with free or
liposomal DxM-P during the time course of AA (for details see Figure 1). * P ≤ 0.05, ** P ≤ 0.01 vs. AA/DxM-P; all Mann Whitney U-test;
administration of free or liposomal DxM-P at the time points 0 hours, 24 hours, and 48 hours.
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lymphocyte apoptosis. Since liposomes are hardly taken
up by lymphocytes in vitro ([42] and own results, data
not shown), direct induction of lymphocyte apoptosis by
liposomal DxM-P is unlikely. Thus, the specific contri-
bution of the prolonged accumulation of liposomal
DxM in the spleen to systemic lymphocyte redistribu-
tion remains to be analyzed.
It is presently unclear whether the therapeutic efficacy
of liposomal DxM-P is due to sustained immunosup-
pression. On one hand, the DTH to pathogenetic Mb
was significantly increased on Day 21 after liposomal
DxM-P treatment when compared to AA/PBS, which
speaks against immunosuppression. This may indicate a
shift of the Th1/Th2 balance [40,43] in favor of a pro-
tective T cell reactivity, for example by modulating the
Mj cytokine pattern [44] and/or by inducing a regula-
tory Th1 type DTH [45]. On the other hand, liposomal
(but also free) DxM-P completely reverted the patholo-
gically increased levels of specific serum anti-Mb IgG
after Day 21; thus, the therapeutic effect of liposomal
DxM-P may at least be partially due to, or associated
with, effects on humoral immunity. However, since total
IgG was not evaluated, it remains unclear whether this
represents broad suppression of the humoral immune
response or rather selective inhibition of disease-trig-
gered immunity. The delay of the effects on the specific
IgG levels compared to those on the cell-mediated
immunity is likely due to the long half-life of the circu-
lating IgG.
Mj were clearly addressed by the liposomal DxM-P,
as shown by a significant, persistent inhibition of the
secretion of pro-inflammatory cytokines in peritoneal
Mj (until five days after the end of therapy). At this
point in time, liposomal DxM-P had little effect on
TNF-a secretion by peritoneal Mj, suggesting that, if
these results are transferable to the arthritic joints [40],
clinical improvement may not be primarily mediated by
local reduction of TNF-a, but rather by reduction of IL-
1b and IL-6.
As described above, clinical efficacy of liposomal
DxM-P may be related to its prolonged circulation in
the blood and its enhanced accumulation in the affected
joint; however, marked accumulation in other immuno-
logically active organs (spleen and liver) is also likely to
influence AA on a local and systemic level. A similar
marked accumulation was observed in the spleen of
AIA rats following injection of our liposomal DxM-P
[19]; thus, the spleen may represent a key efficacy target
of these novel liposomes, in line with the known contri-
bution of the spleen to inflammation severity in acute
AA [40]. On the other hand, liver acumulation may
reduce the number of activated macrophages in the liver
and thereby suppress the subsequent local production of
pro-inflammatory cytokines such as IL-1b [46].
However, in addition to local and systemic depot effects
of liposomal DxM, also non-genomic effects of high
DxM peak levels may contribute to its therapeutic effi-
cacy [38].
The administration of three doses of 1 mg/kg liposo-
mal DxM-P transiently reduced the body weight. This is
a known, rat-specific side-effect of glucocorticoids
(observed at doses above 0.05 mg/kg DxM), mediated
by decreased ribosomal amino acid incorporation into
muscle cells [47], and possibly related to low plasma
levels of released DxM-P [20]. Thus, lymphopenia (see
above) and body weight reduction appeared to be the
only evident side-effects of treatment. Of note, higher
drug adsorption of liposomal DXM-P in tissues and
organs is not associated with stronger GC side effects.
Instead, triggering of the HPA axis, gluconeogenesis or
lymphocyte alterations are markedly reduced in compar-
ison with the effects of free DxM-P [38].
Drug-free liposomes showed a modest pro-inflamma-
tory effect in acute and chronic AA (especially after Day
26). PEGylated liposome formulations are known to
induce allergic reactions [26,48], possibly as a result of
complement activation [49]. However, liposome size
(especially above 90 nm) can also play a key role in
complement activation [50], potentially explaining the
slightly increased lymphocyte number in pop LN
observed with the non-PEGylated PBS-liposomes in our
study (mean size 300 nm). Pro-inflammatory effects in
the arthritic joint, in turn, may be due to increased lipo-
some uptake by activated Mj, possibly triggered by lyso-
somal degradation of DPPC to lyso-phosphatidylcholine,
which significantly increases Mj ingestion [51]. Recent
improvements such as the increase of the drug-to-lipid
ratio may allow diminishing the lipid load [23].
Conclusions
The present investigation on this Mj-targeting formula-
tion is a good example of translational research and
shows that encapsulation of potent anti-inflammatory
steroids has the potential to enhance/prolong therapeu-
tic efficacy and limit side-effects. This preparation may
therefore be suitable to obtain long-lasting effects with
lower or less frequent dosages of GC in non-immuno-
genic drug carriers for the treatment of human diseases
such as RA. Depot and/or recirculation effects in
plasma, inflamed joint, liver, and spleen may contribute
to the enhanced efficacy of liposomally encapsulated
DxM-P.
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